Christophe Weber, Takeda CEO (Shoko Takayasu/Bloomberg via Getty Images)
September 21, 2022 07:40 AM EDT
R&D

Take­da punts dis­ap­point­ing late-stage Mil­len­ni­um drug for $7M in cash

Amber Tong

Take­da has man­aged to of­fload an ex­per­i­men­tal can­cer drug that’s been sit­ting on the shelf — in ex­change for $7 mil­lion in cash plus mile­stones. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Some FDA med­ical de­vice staff re­in­stat­ed just days af­ter re­ceiv­ing pink slips

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Al­con tried to sink Au­ri­on's IPO in 'Valen­tine's Day mas­sacre,' new law­suits say

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times